在B型血友病治疗的临床前和早期阶段试验中使用因子IX兴奋剂
Massimo Franchini1, Daniele Focosi2
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
Expert opinion on investigational drugs
|August 5, 2024
概括
新的B型血友病治疗重点是延长凝血因子IX (FIX) 的半衰期,以减少输液的频率. 这些创新疗法显示出改善患者的前景.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病B是一种罕见的X相关出血疾病,由因子IX (FIX) 缺乏引起.
- 目前的治疗包括使用血衍生或重组产品取代FIX.
- 长效的FIX缩剂改善了治疗的便利性.
研究的目的:
- 审查针对B型血友病的创新血液静止产品的临床前和1/2期研究.
- 为了突出FIX替代疗法的进展.
主要方法:
- 临床前研究的总结.
- 早期临床试验 (1/2期) 的分析.
主要成果:
- 创新的FIX产品旨在进一步延长FIX的半衰期.
- 新型药物处于临床前或临床早期发展阶段.
- 这些产品有可能改善患者的治疗结果和生活质量.
结论:
- 最近的技术进步导致有希望的新型血友病B治疗方法.
- 延长半衰期的FIX产品减少了治疗负担.
- 持续的研究对于使B型血友病患者能够正常生活至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
6.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.7K
Clot Retraction and Fibrinolysis
5.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.1K
Disorders of Hemostasis
768
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
768
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502


